View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

TREAS/IRS RIN: 1545-BQ92 Publication ID: Spring 2024 
Title: ●Sec. 5000D Excise Tax 
Abstract:

This regulatory action prescribes rules related to the tax imposed by 26 U.S.C. 5000D. Section 5000D(a) imposes a tax on the sale of a designated drug by the manufacturer, producer, or importer” of such drug during a day described in section 5000D(b). The section 5000D tax arises in relation to milestones of a prescription drug price negotiation program administered by the Centers for Medicare and Medicaid Services (CMS) (the Program). See sections 119198 of the Social Security Act (SSA). Under the Program, CMS selects a small number of single-source drugs for price negotiation, SSA section 1192(a); authorized generics (meaning, roughly, drugs made under licensing agreements) are treated as single-source drugs, SSA section 1192(e)(2)(A).

 
Agency: Department of the Treasury(TREAS)  Priority: Substantive, Nonsignificant 
RIN Status: First time published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: Undetermined  Unfunded Mandates: Undetermined 
CFR Citation: 26 CFR 47.5000D-0 through -4   
Legal Authority: 26 U.S.C. 5000D    26 U.S.C. 7805   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  07/00/2024 
Additional Information: Drafting attorney: James Williford III, (202) 317-3225 Reviewing attorney: Michael Beker, (202) 317-5258 Treasury attorney: Vivek Chandrasekhar, (202) 622-1082 and Elisabeth Shellan (202) 622-1727 CC:PSI REG-115560-23
Regulatory Flexibility Analysis Required: Undetermined  Government Levels Affected: Undetermined 
Small Entities Affected: No  Federalism: Undetermined 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Agency Contact:
James S. Williford
Attorney
Department of the Treasury
Internal Revenue Service
1111 Constitution Avenue NW, Room 4527,
Washington, DC 20224
Phone:202 317-3225
Email: james.w.williford@irscounsel.treas.gov